Demographic and disease features of cases of GPA and comparators*
| GPA (n=724) | Comparators (n=813)* | P value | |
| Age, mean±SD years | 53.6±16.2 | 56.4±17.1 | 0.001 |
| Sex, no. (%) female | 340 (47.0) | 424 (52.2) | 0.048 |
| Maximum serum creatinine, mean | 0.077 | ||
| μmoles/L | 168.3 | 185.2 | |
| mg/dL | 1.9 | 2.1 | |
| cANCA positive, no. (%) | 531 (73.3) | 40 (4.9) | <0.001 |
| pANCA positive, no. (%) | 71 (9.8) | 342 (42.1) | <0.001 |
| Anti-PR3-ANCA positive, no. (%) | 595 (82.2) | 21 (2.6) | <0.001 |
| Anti-MPO-ANCA positive, no. (%) | 59 (8.1) | 399 (49.1) | <0.001 |
| Maximum eosinophil count ≥1×109/L, no. (%) | 196 (27) | 366 (45) | <0.001 |
*Diagnoses of comparators for the classification criteria for granulomatosis with polyangiitis (GPA) included microscopic polyangiitis (n=291), eosinophilic granulomatosis with polyangiitis (n=226), polyarteritis nodosa (n=51), non-ANCA-associated small-vessel vasculitis that could not be subtyped (n=51), Behçet’s disease (n=50), IgA vasculitis (n=50), cryoglobulinaemic vasculitis (n=34), ANCA-associated vasculitis that could not be subtyped (n=25), primary central nervous system vasculitis (n=19) and antiglomerular basement membrane disease (n=16).
ANCA, antineutrophil cytoplasmic antibody; anti-MPO-ANCA, anti-myeloperoxidase-ANCA; anti-PR3-ANCA, anti-proteinase 3-ANCA; cANCA, cytoplasmic antineutrophil cytoplasmic antibody; GPA, granulomatosis with polyangiitis; pANCA, perinuclear ANCA.